ADVERTISEMENT

Generic Drugs

Reddy’s To Keep Producing Semaglutide In India As Novo Denied Interim Relief

A Delhi High Court has declined Novo Nordisk’s bid to halt Reddy’s ongoing production, allowing exports while patent validity proceeds to trial.

Only One ANDA Was Submitted To The US FDA During The Shutdown; It Should Have Been None

The FDA said an ANDA managed to be submitted during a period when no new ANDAs could be accepted.

EPO Appeal Board Strikes Down Biogen’s European Tecfidera Patent

EPO Appeal Board overturns earlier ruling and invalidates Biogen’s 480mg Tecfidera patent, clearing the way for broader dimethyl fumarate competition in Europe.

Pricing Peak Propels Propranolol To Pole Position In November

Propranolol prices that were almost five times higher in November meant that the beta-blocker topped our table of UK price rises this month, as ciprofloxacin prices also continued to climb.

Amneal Scores Dual FDA Wins In High-Value Complex Generics

Back-to-back FDA nods for generic Restasis and ProAir highlight Amneal’s growing strength in complex sterile and inhalation manufacturing.

GDUFA IV: US FDA Wants to ‘Streamline’ Formal Meeting Structure

The FDA proposed changes to the formal meeting system for sponsors in the next generic drug user fee program cycle, in part to speed timelines.

Broad Korea Pricing Reforms Aim To Promote Innovation, Ensure Essential Drug Supply

South Korea has laid out comprehensive drug pricing reforms that aim to enhance patient access to treatment, accelerate innovation and stabilize essential drug supplies, but the industry is concerned it could lead to weaker R&D and manufacturing and increased dependency on high-priced imports.

European Commission Dismisses Calls For Pause On Waste Water Directive

The European Commission says it will soon publish an updated study on the impact of the Urban Waste Water Treatment Directive on the pharmaceutical and cosmetics industry and that it would support member states in avoiding “unintended consequences.”

Lupin Eyes Global Ophthalmology Growth

Entering 2026, Lupin is positioning itself for growth, with a keen focus on the expanding ophthalmology market.

What’s Next? Five Things To Look Out For In December 2025

Generics Bulletin previews the most noteworthy and anticipated events for December 2025.

US Makes First Reformulated Ranitidine Approval Since Withdrawal, Starting With Rx Tablets

In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.

US FDA’s Advertising Enforcement Crackdown Expands To Generic Drugs

A webpage for PharmaTher’s ketamine product lacked risk information and made misleading claims about the approved indication, the FDA said in a rare ad/promo violation letter to an ANDA holder.